Speaking proposals are still being accepted! Click here to submit a proposal for review.
Early Stage Molecular Diagnostics - Overview | Day 1 | Joint Sessions | Emerging Targeted Oncology
Downloads
Early Stage Molecular Diagnostics PDF | Emerging Targeting Oncology PDF
Particularly efficient for promoting discussion of partnerships, the Early Stage Molecular Diagnostics Partnering Forum is designed for both the emerging companies with promising technology and applications, and more established companies looking to collaborate with these companies.
Reasons to Attend
- Opportunities for scheduled one-on-one meetings and unscheduled networking with company presenters
- 20 Companies focused on Cancer-related diagnostics
- 40 Emerging Company Presentations including point-of-care, rapid diagnostic platforms, novel amplification and automated sample processing approaches, diagnostics for infectious disease, cardiovascular, CNS, pregnancy and other disorders
- Panel Discussions with Program Advisors
- Diagnostics based on DNA sequencing, genotyping and mutation analysis, gene expression signatures, protein biomarkers and protein signatures, protein post-translational modification and autoantibodies, microbiome analysis
Program Advisory Board Includes:
- Abbott Molecular
- BD Diagnostics
- BioMerieux
- Bristol Myers Squibb
- DAKO
- Diaceutics
- Genomic Health
- Gen-Probe
- Illumina
- LabCorp
|
- Leomics Consulting
- MDX Consulting
- Medco Health Solutions
- QIAGEN
- Roche Diagnostics
- Scientia Advisors
- SONY DADC
- Versant Ventures
|